Paper Details

  1. Home
  2. Paper Details

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.

Author: AdamsAubrey M, BursteinRami, DodickDavid W, FinneganMichelle, GoadsbyPeter J, KuangAmy W, LaiJeff, LiptonRichard B, TrugmanJoel M, YuSung Yun

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treatment of migraine with ubrogepant when pain is mild resulted in significantly higher rates of pain freedom, absence of symptoms, and normal function within 2 hours postdose compared to treatment during moderate or severe pain.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND OBJECTIVES: To examine the efficacy of ubrogepant in the treatment of migraine with mild vs moderate or severe pain. METHODS: This was a phase 3, open-label, dose-blinded, 52-week extension trial. Adults with migraine were randomized 1:1:1 (usual care, ubrogepant 50 mg, or ubrogepant...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620813/

データ提供：米国国立医学図書館（NLM）

Efficacy of Ubrogepant for Migraine with Different Pain Intensities

Migraine is a common and debilitating headache disorder that can significantly impact quality of life. This study examined the efficacy of ubrogepant, a medication for the acute treatment of migraine, in patients with mild pain versus moderate or severe pain.

Ubrogepant's Effectiveness for Migraine

The study found that ubrogepant was more effective in achieving pain freedom, freedom from associated symptoms, and normal function within 2 hours after administration when used to treat migraine with mild pain compared to moderate or severe pain. This suggests that ubrogepant may be particularly effective for individuals experiencing milder migraine attacks.

Optimizing Migraine Treatment

This research provides valuable insights into the potential benefits of ubrogepant for migraine, especially in patients with mild pain. The findings emphasize the importance of considering pain intensity when selecting treatment options for migraine.

Dr.Camel's Conclusion

This study offers valuable insights into the efficacy of ubrogepant for migraine, highlighting the importance of tailoring treatment to the individual needs of each patient. Like a camel navigating a desert oasis, healthcare providers should carefully consider the pain intensity and other factors when selecting the most effective migraine treatment options.

Date :
  1. Date Completed 2022-10-26
  2. Date Revised 2022-12-15
Further Info :

Pubmed ID

35977836

DOI: Digital Object Identifier

PMC9620813

Related Literature

Article Analysis
・Effects of ubrogepant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.